Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 34:504-510
Objectives: The present study aimed to retrospectively compare the clinical and imaging characteristics and laboratory data of patients with malignant tumor concurrent with acute ischemic ...
Autor:
Seong-Jang Kim, Samuel Chang
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 31:1-6
This study was aimed to define the predictive values of preoperative Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) parameters and compared to define effective parameters for prediction of overall su
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 30:305-309
The objective of this study was to examine indicators of liver function and inflammation for prognostic value in predicting outcomes to yttrium-90 radioembolization (RE). In a retrospective analysis, markers of liver function and inflammation, biomar
Autor:
Francine M. Quan, Walter D.Y. Quan
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 29:58-61
Outpatient daily intravenous infusions of interleukin-2 (IL-2) have been developed to maintain anticancer activity and decrease toxicity of this agent against kidney cancer. Lymphokine activated killer cell (LAK) numbers are increased with these IL-2
Autor:
Feng Wang, Qian-zhi Wu, Ling-quan Lu, Xiaofeng Li, Liwei Wang, Baozhong Shen, Jianping Gu, Xindao Yin
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 28:731-736
The objective of this study was to evaluate the clinical value of combination of diagnostic computed tomography (CT) and somatostatin receptor imaging with (99m)Tc-octreotide acetate SPECT/CT in differentiation of benign pulmonary nodules from cancer
Autor:
Fabrizio Drudi, Jacopo Giuliani
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 27:513-518
Currently, the best sequence of targeted therapy in patients with metastatic renal cell carcinoma (mRCC) has not been sufficiently defined and is based on the patient's and physician's decision, which may be influenced by comorbidities and toxicity p
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 26:753-757
Twenty-nine (29) patients with recurrent head and neck carcinomas underwent (125)I seed permanent implantation under ultrasonography guidance and the feasibility and efficacy of (125)I seed implantation were assessed. The postplan evaluation showed t
Autor:
Warren H. Fong, Louis A. VanderMolen, Robert O. Dillman, Khosrow Mahdavi, Neil M. Barth, Stephanie E. McClure
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 26:273-277
Interleukin-2 (IL-2) was the preferred treatment for medically fit patients with advanced kidney cancer, but recently, several targeted therapies have been approved for metastatic renal cell carcinoma. We wished to determine the long-term survival ra
Autor:
Christian Rabe, Jan Bucerius, Hans-Peter Fischer, Dirk Pauleit, Jörn Risse, Hans Bender, Hans-Jürgen Biersack
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 24:445-452
The diagnostic accuracy of 18F-FDG-PET (fluoro-2-deoxyglucose-positron emission tomography) remains questionable for primary hepatocellular carcinoma (HCC) but seems to be more promising for restaging and therapy control. Yet, there are no data on FD
Autor:
Takafumi Maekawa, Toshimi Sakai, Takayuki Shirakusa, Yuichi Yamashita, Seiichiro Hoshino, Kouji Mikami
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 23:461-468
Long-term survival, which extends beyond 5 years, is a desired outcome for colorectal cancer patients. In the present study, we retrospectively compared the 10-year overall survival between the control group and the polysaccharide kureha (PSK) group